Search the Newsreel

666,728 Shares in Hershey Company (The) $HSY Bought by Deutsche Bank AG

Deutsche Bank AG acquired a new stake of 666,728 shares in The Hershey Company, valued at approximately $116.98 million, during the second quarter. This purchase represents about 0.33% of Hershey's stock. Other institutional investors like Vanguard Group Inc., Capital International Investors, and State Street …

20,453 Shares in Archer Daniels Midland Company $ADM Acquired by Foster & Motley Inc.

Foster & Motley Inc. recently acquired 20,453 shares of Archer Daniels Midland Company (NYSE:ADM) valued at approximately $1.563 million. This new stake was part of broader institutional investor activity in ADM during the second quarter, with several other firms also purchasing new positions. Analyst …

Zacks Industry Outlook U.S. Bancorp, State Street, and Northern Trust

Aurora Investment Counsel Takes Position in Halozyme Therapeutics, Inc. $HALO

Aurora Investment Counsel has acquired a new stake of 18,233 shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO), valued at approximately $1.43 million, during the second quarter. This move is part of broader institutional investor activity, with several other firms also adjusting their holdings in the …

Price to book forward of TG Therapeutics, Inc. – BX:NKB2

This article provides a brief financial data point for TG Therapeutics, Inc. (BX:NKB2) focusing on its forward price-to-book ratio. The content indicates a period value, change, and percentage change for this metric, suggesting it is a snapshot of recent financial performance. The article appears …

Cardiol Therapeutics Inc (CRDL) Stock Price, Trades & News

Element Pointe Advisors LLC Invests $836,000 in Thermo Fisher Scientific Inc. $TMO

Element Pointe Advisors LLC acquired a new stake of 1,668 shares, valued at $836,000, in Thermo Fisher Scientific Inc. during the second quarter. Other institutional investors have also increased their holdings, with BlackRock Inc. buying a significant new position worth over $15 billion. The …

First National Bank of Omaha Buys New Position in Thermo Fisher Scientific Inc. $TMO

First National Bank of Omaha has acquired a new position in Thermo Fisher Scientific Inc. (NYSE:TMO), purchasing 27,553 shares valued at approximately $13.895 million. This move is part of broader institutional interest, with several other firms also adjusting their stakes in the medical research …

Janux (JANX) Latest Quarter: EPS Lands Above Forecast; Market Reaction: Shares Finish 3.30% Higher on the Day - Estimate Revision Count

First National Bank of Omaha Buys Shares of 76,613 Northern Oil and Gas, Inc. $NOG

First National Bank of Omaha has acquired 76,613 shares of Northern Oil and Gas, Inc. (NYSE:NOG) in the second quarter, representing a new position valued at approximately $1.39 million. Other institutional investors have also adjusted their holdings in NOG, with the stock currently having …

3,366 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by BOK Financial Private Wealth Inc.

BOK Financial Private Wealth Inc. acquired 3,366 shares of Thermo Fisher Scientific Inc. (NYSE:TMO) for approximately $1.69 million in the second quarter. Institutional investors and hedge funds own 89.23% of the company, which recently reported strong quarterly earnings with $6.03 EPS and $11.99 billion …

Ovid Therapeutics Inc. (OVID) Latest Stock News & Headlines

8,967 Shares in The Sherwin-Williams Company $SHW Purchased by Asahi Life Asset Management CO. LTD.

Asahi Life Asset Management CO. LTD. acquired a new stake of 8,967 shares in The Sherwin-Williams Company (NYSE:SHW) during the second quarter, valued at approximately $3.088 million. This investment makes Sherwin-Williams the 13th largest holding in Asahi Life Asset Management's portfolio, representing about 1.7%. …

Shield Therapeutics cuts H1 loss as ACCRUFeR growth drives revenue higher

Abacus FCF Advisors LLC Purchases New Shares in Archer Daniels Midland Company $ADM

Abacus FCF Advisors LLC has acquired a new position of 103,898 shares in Archer Daniels Midland Company (NYSE:ADM), valued at approximately $7.94 million, making it their 29th largest holding. Several other institutional investors also adjusted their stakes in ADM. The article details ADM's recent …

2,463 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by Alpine Woods Capital Investors LLC

Alpine Woods Capital Investors LLC recently purchased 2,463 shares of Thermo Fisher Scientific (NYSE:TMO) valued at approximately $1.24 million in the second quarter. Other institutional investors have also adjusted their holdings in the company, with institutional investors and hedge funds collectively owning 89.23% of …

AssuredPartners Investment Advisors LLC Makes New Investment in Southern Company (The) $SO

AssuredPartners Investment Advisors LLC has initiated a new position in Southern Company (NYSE:SO), purchasing 13,670 shares valued at approximately $1.31 million. Other institutional investors have also adjusted their holdings, with institutional ownership of the utility’s stock at 64.1%. Southern Company reported strong quarterly earnings, …

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Recommendation of "Hold" by Brokerages

Fate Therapeutics, Inc. (NASDAQ:FATE) has received a consensus "Hold" rating from eight brokerages, with an average 12-month price target of $5.90. The biopharmaceutical company, which focuses on iPSC-derived cellular immunotherapies, reported quarterly revenue of $2.08 million and an adjusted loss of $0.25 per share, …

David Kirn plans $1.16M 4D Molecular (NASDAQ: FDMT) stock sale

David Kirn, an officer at 4D Molecular Therapeutics, Inc. (FDMT), plans to sell 69,076 shares of Class A Common Stock valued at approximately $1.16 million through Goldman Sachs & Co. LLC. This sale is part of a Rule 10b5-1(c) selling plan initiated on January …

United Therapeutics (UTHR) CEO sells shares under preset trading plan

Martine Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), through a family trust, exercised 9,500 stock options at $135.42 per share and then sold the corresponding 9,500 common shares in multiple open-market trades at weighted average prices around the low-$500s per share on August …

Relay Therapeutics, Inc. $RLAY Shares Bought by Bank of America Corp DE

Bank of America Corp DE significantly increased its stake in Relay Therapeutics (NASDAQ:RLAY) by 86.1% during the first quarter, now owning 1.01% of the company's stock valued at $19.28 million. Other institutional investors and hedge funds also made substantial changes to their positions, with …

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by Analysts

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $56.08, exceeding its current share price of $41.70. While recent analyst actions were mixed, including Guggenheim raising its target to $100 and Cantor Fitzgerald …

Northern Star Resources (ASX:NST) Delivers Record Profit Amid Growth and Governance Focus

Herbalife (HLF) Results Versus Estimates: EPS Falls Short of Its Estimate at the Close; Stock Move: The Stock Gains 0.89% on the Day - EPS Surprise History

SAB (SABS) Earnings Update: EPS Prints Above Forecast in the Current Update; Market Move: Shares Move Lower 0.26% in the Latest Session - ROE Trend Analysis

BridgeBio (BBOT) Financial Results: The EPS Result Is Above Expectation in the Current Update; Share Response: Shares Move 7.26% Up - One-Time Gain Impact

Artiva (ARTV) Earnings Update: The Bottom-Line Figure Outpaces Its Comparison on the Day; Post-Report: The Market Price Moves 0.17% Higher for the Current Session - EPS Revision Trend

Shield Therapeutics narrows losses as ACCRUFeR® growth and global milestones lift H1 revenue

Southern Cross Electrical Engineering (ASX:SXE): What’s Really Behind the Earnings Surprise?

Anika Therapeutics (NASDAQ:ANIK) Stock Price Passes Above Two Hundred Day Moving Average - Here's Why

Anika Therapeutics (NASDAQ:ANIK) stock recently surpassed its 200-day moving average of $14.84, closing at $21.26, despite a 1.4% dip during the session. Analyst sentiment has improved, with B. Riley raising its price target to $21 and Wall Street Zen and Zacks upgrading the stock …

Is Spyre Therapeutics (SYRE) Fully Priced After Its SPY772 Program And SKYLIGHT Trial Launch?

Spyre Therapeutics (SYRE) has launched its SPY772 combination program and initiated the SKYLIGHT Phase 2 trial for Hidradenitis Suppurativa, targeting dual inhibition of TL1A and IL-17A/F. Despite strong recent share price performance and a P/B ratio of 10.1x (compared to the US biotech average …

Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform (NASDAQ:TRVI)

Trevi Therapeutics is positioned to leverage its drug Haduvio to target IPF-related chronic cough, with plans to expand into non-IPF ILD and refractory chronic cough. The company's strategy focuses on concentrated pulmonology networks, enabling efficient market entry and growth. With positive Phase II data, …

Cadrenal (CVKD) Results Check: EPS Clears the Reported Estimate; After Results: Shares Move 4.09% Down on the Day - Slow Growth Warning

Stoke (STOK) Results Breakdown: The Available Earnings Metric Delivers a Miss in the Reported Period; Share Response: The Stock Records a 2.77% Increase in the Latest Reading - Performance Review

Fletcher Earnings: A Return to Profitability Despite Low Activity in Residential Construction

Is Coherent (COHR) Undervalued Following Record Revenue And AI Data Center Growth?